Thursday, May 25, 2017 6:20:08 PM
ISA investigation regarded "dissemination" of data.
So .... we all should understand that we have not invested in Pfizer .... Kitov is a Israeli nano cap with approx 5 employees and with very promising drugs, one of them a potential blockbuster that successfully passed phase 3. If you check the filing you could find out many reasons that could explain the delays .... the requested did by FDA in the pre-meeting NDA for example. In the meanwhile, after data results, during 2016, KIT-302 has been patented ....
What I'm trying to say you is that if you believed in KIT-302 and Waymack before, there is not reason you shouldn't now.
Kitov potential has been reviewed several time by Dexcel (that recently asked for filing a patent application together), by Kunhil Pharma and the last one by GHP partners (Gil Pogozelich recently sold a company he owned for more than $20mm), that accepted to sell Tyrnovo for Kitov shares and now owns 6,8% stake in Kitov (and this is not just an asset, this is science, years of work and research .... Alexander Levitzki says you something?) ....
More reasons to be optimistic. Lot of catalysts ahead.
All the best.
EnricoMania
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM